Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NMES1/C15orf48 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NMES1/C15orf48 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View NMES1 Products |
| Gene Delivery | NMES1/C15orf48 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View NMES1 Products |
| Benchmark Ab | Anti-NMES1/C15orf48 Recombinant positive control. |
View NMES1 Products |
| Validator | NMES1/C15orf48 siRNA Set For knockdown verification. |
View NMES1 Products |
| Related Target A | COX4I1 Core subunit of Cytochrome c oxidase (Complex IV) for interaction studies. |
View COX4I1 Products |
| Related Target B | COX4I2 Isoform of COX4 involved in hypoxic response and Complex IV regulation. |
View COX4I2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial Complex IV Integration | Lentivirus for Stable Cell Line generation to preserve native mitochondrial localization. |
| Specificity against other COX subunits | Sequence Verified constructs and high-purity (>95%) recombinant proteins. |
| Lack of Controls | Recombinant positive control antibodies included. |
| False Positives | Sequence-specific siRNA included for knockdown specificity checks. |
Live NMES1/C15orf48 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The role of NMES1 (C15orf48 / COXFA4L3) is gaining attention in the fields of immunometabolism and oncology. As an accessory subunit of mitochondrial Cytochrome c oxidase (Complex IV), it plays a critical role in oxidative phosphorylation (OXPHOS). Downregulation of NMES1 is frequently observed in esophageal squamous cell carcinoma, while its modulation in macrophages affects inflammatory responses. Future R&D is heavily focused on targeting tumor metabolism and overcoming metabolic resistance in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic/Early Biotech | Metabolic Disorders, Cancer | Metabolic profiling (Need Stable Cell Lines via Lentivirus) |
| Gene Therapy / RNAi | Emerging Biopharma | Esophageal Cancer | Target Validation (Need Validated siRNA sets) |
| Biomarker Diagnostics | Diagnostic Labs | Oncology Profiling | Detection optimization (Need High-Purity Antigens) |